Corcept Therapeutics Incorporated (CORT)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 127,665 | 137,289 | 128,588 | 149,750 | 135,551 | 111,800 | 172,377 | 465,057 | 436,619 | 50,243 | 381,976 | 61,862 | 335,812 | 94,688 | 95,430 | 52,381 | 476,892 | 30,560 | 58,523 | 349,005 |
| Short-term investments | US$ in thousands | 255,669 | 243,047 | 344,568 | 261,011 | 232,670 | 243,425 | 190,885 | 165,115 | 365,343 | 346,019 | 334,740 | 283,665 | 145,918 | 266,643 | 274,552 | 320,578 | 364,506 | 398,233 | 346,835 | 222,838 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 140,773 | 126,216 | 100,750 | 97,202 | 104,505 | 121,873 | 93,059 | 25,216 | 81,588 | 53,068 | 54,038 | 57,244 | 6,908 | 44,757 | 45,402 | 40,601 | 10,554 | 43,048 | 42,243 | 36,005 |
| Quick ratio | 2.72 | 3.01 | 4.70 | 4.23 | 3.52 | 2.91 | 3.90 | 24.99 | 9.83 | 7.47 | 13.26 | 6.04 | 69.74 | 8.07 | 8.15 | 9.19 | 79.72 | 9.96 | 9.60 | 15.88 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($127,665K
+ $255,669K
+ $—K)
÷ $140,773K
= 2.72
The quick ratio of Corcept Therapeutics Incorporated fluctuated over the reported periods, indicating shifts in the company's liquidity position. The quick ratio measures the company's ability to meet its short-term obligations with its most liquid assets.
From March 31, 2020, to December 31, 2024, the quick ratio varied between 2.91 and 79.72. The highest quick ratio of 79.72, recorded on December 31, 2020, suggests that the company had a significant amount of highly liquid assets relative to its current liabilities at that point. This indicates that Corcept Therapeutics had a strong ability to cover its short-term debts if needed.
Conversely, the lowest quick ratio of 2.91, reported on September 30, 2023, reflects a decreased level of liquidity, indicating that the company may have had difficulty meeting its short-term obligations with its readily available liquid assets during that period.
Overall, while the quick ratio fluctuations demonstrate varying levels of liquidity for Corcept Therapeutics, it is essential to consider additional financial metrics and factors when evaluating the company's overall financial health and sustainability.
Peer comparison
Dec 31, 2024